← Back to Search

EQUITY GI for Gastrointestinal Cancer

N/A
Waitlist Available
Led By Sakti Chakrabarti, MD
Research Sponsored by Case Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Newly diagnosed Black GI cancer participants irrespective of stage. Eligible tumor types include anal carcinoma, rectal cancer, colon cancer, small bowel cancer, appendix carcinoma, hepatobiliary cancer, pancreatic cancer, gastroesophageal cancer, gastrointestinal neuroendocrine tumors, and gastrointestinal stromal tumor
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to improve the care of individuals with gastrointestinal cancer. It has three main parts: ensuring proper biomarker testing and evidence-based care, helping participants enroll in clinical trials, and increasing health literacy

Who is the study for?
This trial is for Black adults aged 18 or older who have been newly diagnosed with various types of gastrointestinal cancers, including those affecting the colon, rectum, stomach, pancreas, liver and more. Participants must be able to follow study procedures and give informed consent.
What is being tested?
EQUITY GI aims to improve care quality by ensuring proper biomarker testing for personalized treatment plans and assisting with clinical trial enrollment. It also focuses on enhancing health literacy through educational materials about participants' conditions.
What are the potential side effects?
Since this study involves standard-of-care treatments rather than experimental drugs, side effects will vary based on individual treatments received. These could range from digestive issues to fatigue or skin reactions depending on the specific therapies.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am Black and have a newly diagnosed GI cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Biomarker testing rate of Black participants diagnosed with GI cancer
Secondary study objectives
Change in Health literacy score among black participants diagnosed with GI cancer
Change in Health literacy test among black participants diagnosed with GI cancer
Clinical trial enrollment rate among black participants diagnosed with GI cancer

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: EQUITY GIExperimental Treatment1 Intervention
1. Data gathering 2. Program development and implementation 3. Health literacy

Find a Location

Who is running the clinical trial?

Case Comprehensive Cancer CenterLead Sponsor
468 Previous Clinical Trials
33,223 Total Patients Enrolled
Sakti Chakrabarti, MDPrincipal InvestigatorUniversity Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
1 Previous Clinical Trials
~133 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top